BPH & Male LUTS
This atlas page is the treatment-selection hub for benign prostatic hyperplasia (BPH), benign prostatic obstruction (BPO), and bothersome male lower urinary tract symptoms (LUTS). It deliberately separates the procedural choice from the disease background: for pathophysiology, complications, natural history, and medication pharmacology, see Benign Prostatic Hyperplasia, Alpha Blockers, 5-alpha Reductase Inhibitors, PDE5 Inhibitors, Anticholinergics, and Beta3 Agonists.
The operative question is what the least invasive treatment is that will solve this patient's dominant problem without spending the outcome they care about most.
The 2026 AUA BPH guideline, published online May 7, replaces the 2023 amendment as the current reference. Its three parts cover evaluation (Part I),[11] medical therapy (Part II),[14] and procedural / surgical treatment (Part III);[12] the evidence search extends through December 15, 2025. Shared decision-making should explicitly address expected symptom relief, durability, sexual effects, retreatment, and follow-up. Older edition-specific statements on individual pages should be checked against the current AUA guideline and the relevant device instructions before applying eligibility criteria.
General Principles
- Benign Prostatic HyperplasiaBPH terminology, static vs dynamic obstruction, bladder remodeling, red flags, medical therapy, retention pathway, complications, and reconstructive pitfalls.
- Prostate Enucleation / HoLEPAnatomic endoscopic enucleation, HoLEP equipment and laser settings, classic vs en-bloc / early-apical-release technique, morcellation safety, anticoagulation, continence, sexual function, incidental cancer, and learning curve.
- Energy Devices for BPHTUR physics, bipolar energy, GreenLight photovaporization, HoLEP / laser enucleation, thulium platforms, aquablation, and energy-specific safety trade-offs.
- UroLift / Prostatic Urethral LiftPermanent implant mechanics, lateral-lobe compression, ejaculation-preserving rationale, and device-specific limitations.
Decision Framework
1. Name the symptom phenotype
Male LUTS should be sorted into three overlapping buckets before treatment selection:[1][2]
| Phenotype | Symptoms | Practical implication |
|---|---|---|
| Voiding / obstructive | Hesitancy, weak stream, intermittency, straining, incomplete emptying | Think BPO, urethral stricture, bladder neck stenosis, dysfunctional voiding, or detrusor underactivity |
| Storage / irritative | Frequency, urgency, nocturia, urgency incontinence | Think OAB, obstruction-driven detrusor overactivity, nocturnal polyuria, diuretics, sleep disease, diabetes, or neurologic disease |
| Post-micturition | Post-void dribbling, terminal dribble, incomplete-emptying sensation | Often mixed outlet + pelvic-floor + urethral trapping physiology |
Mixed symptoms are the rule. The dominant bother determines the first treatment target, while the outlet evaluation determines whether storage-directed treatment is safe.[4][5]
2. Perform the core evaluation
For all men with bothersome LUTS, the core evaluation should document baseline severity, screen for alternative diagnoses, and identify complications that force early intervention.[1][2][3]
| Element | What it answers |
|---|---|
| History + medication review | Fluid timing, caffeine/alcohol, diuretics, anticholinergics, antihistamines, sympathomimetics, opioids, neurologic disease, constipation, sleep symptoms, sexual function |
| IPSS / QoL score | Severity: mild 0-7, moderate 8-19, severe 20-35; a 3-point decrease is usually clinically meaningful |
| Focused exam + DRE | Prostate texture, nodularity, neurologic clues, palpable bladder; DRE estimates volume poorly |
| Urinalysis | Infection, hematuria, glycosuria, proteinuria |
| PSA when it will change management | Cancer-screening decision and surrogate for gland size / progression risk; PSA >1.5 ng/mL often suggests prostate volume >30 mL[2] |
| PVR | Emptying safety, retention risk, antimuscarinic / beta3 safety |
| Uroflowmetry | Qmax and curve shape; low flow can mean obstruction or weak detrusor |
| Diary / frequency-volume chart | Nocturia, polyuria, urgency, and fluid-timing mismatch |
Pre-procedural planning should add prostate volume and shape assessment, median-lobe / intravesical protrusion assessment, and cystoscopy or urodynamics when the diagnosis is uncertain or the result would change the procedure.[2]
3. Identify early-procedure triggers
Do not slowly escalate medication when BPH is already complicated. Move to urologic procedural planning when any of the following are present:[1][2]
- Refractory, recurrent, or catheter-dependent urinary retention
- Recurrent UTI attributable to incomplete emptying
- Bladder stones
- Recurrent gross hematuria attributed to BPH after malignancy / stone evaluation
- Hydronephrosis or renal deterioration from outlet obstruction
- Large or rising PVR with decompensation concern
- Patient preference to avoid chronic medication after informed counseling
4. Choose a path by bother, risk, anatomy, and preference
| Clinical scenario | First treatment path | When to move on |
|---|---|---|
| Mild or non-bothersome LUTS | Watchful waiting with lifestyle / behavioral changes; EAU 2026 advises review at six months, then annually if stable[2] | Worsening IPSS, new bother, retention, hematuria, infection, stones, renal deterioration |
| Bothersome moderate-to-severe LUTS, no complications | Discuss behavioral, medical, and procedural options in light of patient goals | Reassess benefit, burden, adverse effects, and preference at follow-up |
| Voiding-predominant, any prostate size | Alpha blocker; tadalafil if ED / sexual-function priority and no nitrate contraindication | Persistent obstruction or recurrent retention |
| Large prostate / PSA surrogate / progression risk | 5-ARI, often with alpha blocker during onset period | Persistent bother after 6 months or complications |
| Storage-predominant with acceptable PVR | Beta3 agonist or antimuscarinic, usually after outlet risk is assessed; the EAU guideline advises against antimuscarinics when PVR is > 150 mL [2] | Persistent urgency after outlet therapy or unsafe emptying |
| Complicated BPH or refractory LUTS | Procedure selected by prostate size, median lobe, retention status, anticoagulation, sexual goals, anesthetic risk | Retreatment or salvage pathway if symptoms recur |
5. Select the procedure by the trade-off the patient accepts
TURP, HoLEP / endoscopic enucleation, and simple prostatectomy remain the durability anchors. In a 2023 network meta-analysis, short-term symptom and quality-of-life outcomes after PAE, PUL, and water vapor therapy appeared similar to TURP; TURP produced greater flow gains, while ejaculatory outcomes favored water vapor therapy and PUL.[7] A 2021 Cochrane review found major-adverse-event and retreatment comparisons uncertain for several MISTs.[6]
| Priority | Better-fitting options | Main caution |
|---|---|---|
| Maximum durability / strongest deobstruction | HoLEP / laser enucleation, bipolar TURP, simple prostatectomy for very large glands | Ejaculatory dysfunction is common; transient incontinence can follow enucleation |
| Very large gland | HoLEP / enucleation, robotic or open simple prostatectomy, selected Aquablation for 80–150 mL glands (WATER II single-arm cohort)[2], PAE in selected high-risk patients | Office MISTs may underdeliver when bulk reduction is needed. WATER III found similar three-month IPSS changes after Aquablation and laser enucleation in 80–180 mL glands, but only 66 of 170 men with three-month data were randomized; comparative durability remains unknown.[18] |
| Bleeding risk / anticoagulation | GreenLight PVP, HoLEP in expert hands, PAE in selected patients | Anticoagulation strategy still requires proceduralist-specific planning |
| Ejaculation preservation | PUL, water vapor thermal therapy, iTIND, aquablation, Optilume BPH | Usually accepts less deobstruction, slower onset, or less mature retreatment data; in network meta-analysis, ejaculatory function favored water vapor therapy and PUL over TURP[7][8][9]. In the FDA iTIND pivotal trial, the prespecified three-month IPSS comparison with sham was not statistically significant (p = 0.104), although the 12-month within-group co-primary endpoint was met.[20] The Optilume BPH label contraindicates use in patients with known hypersensitivity to paclitaxel or structurally related compounds, active urinary tract infection, an artificial urinary sphincter, or a penile prosthesis. It advises abstinence or condom use for 30 days after treatment and highly effective contraception for men with partners of childbearing potential to avoid fathering a child for at least 12 months after treatment.[16] |
| Median lobe / intravesical protrusion | TURP, HoLEP / enucleation, aquablation, water vapor therapy in selected median lobes | Classic PUL selection is less favorable for obstructive median-lobe anatomy.[9][2] |
| Office / ambulatory treatment | PUL, water vapor therapy, iTIND, Optilume BPH, PAE | PUL has a higher retreatment rate than TURP; a systematic review also found higher reintervention after PAE than TURP or enucleation. Direct long-term comparisons with TURP or HoLEP remain limited for water vapor therapy, iTIND, and Optilume BPH.[2] |
| Catheter-dependent retention | HoLEP / enucleation, TURP, simple prostatectomy (AUA 2026 recommends a resective technology, Expert Opinion)[12]; selected PAE if surgical risk is prohibitive | PAE may yield similar IPSS improvement to TURP at 12 weeks–12 months in mixed LUTS/BPO trials, but likely has more retreatment.[10] In one five-year RCT, 20/48 PAE-treated men underwent TURP and only 18/48 attended five-year follow-up; catheter-free outcomes for the 9/48 with baseline indwelling catheters were not reported separately.[17] Confirm detrusor contractility when chronic retention suggests underactive bladder |
Technique Database
| Technique | Family | Typical Volume | Best Anatomy | Sexual Function |
|---|---|---|---|---|
| TURP | Resection | 30–80 mL <Rec>(EAU strong recommendation)</Rec> | Lateral and median lobe | RE 60–75%; ED 14% (Wei et al. 2025 review) |
| TUIP | Incision | ≤ 30 g | Small gland; no median lobe | Retrograde ejaculation 11% in one long-term TUIP series (Sirls 1993) and 35% among sexually active men in one RCT (Riehmann 1995) |
| Anatomical Enucleation of the Prostate | Enucleation | Any size | Lateral, median, retention, large gland | ES-ThuLEP preserved ejaculation in 219/283 (77.4%) at 6 months in one prospective cohort (Bozzini 2021) |
| GreenLight PVP | Vaporization | 30–80 mL <Rec>(EAU strong recommendation for specified PVP lasers)</Rec>; FDA clearance has no volume cutoff | Lateral and median lobe | Antegrade ejaculation in 85% of assessed hood-sparing versus 31.6% of assessed standard-PVP patients in a 49-man RCT followed through 12 months (Abolazm 2020)<sup>[[21]](#ref21)</sup> |
| Aquablation | Robotic | 30–150 mL (WATER / WATER II range) | Lateral and median lobe | Antegrade ejaculation preserved in 81–90% at five years in WATER/WATER II cohorts (EAU 2026 guideline [2]) |
| Simple Prostatectomy | Adenomectomy | > 80 mL | Very large gland; bladder pathology | Conventional simple prostatectomy: RE 80–90% (Wei et al. 2025 review); Madigan RASP aims to preserve ejaculation |
| UroLift | MIST | 30–80 mL (AUA 2026) | Lateral lobe; no obstructing median lobe per AUA 2026 (MedLift studied selected median lobes) | 0% pooled anejaculation in a 24-study MIST review; follow-up mainly ≤ 24 months (Franco 2026) |
| Rezūm | MIST | FDA 30–150 mL (men 50 or older; see cited note) | Lateral lobes; FDA indication also specifies central-zone and/or median-lobe hyperplasia | 3% pooled anejaculation in a MIST review; follow-up mainly ≤ 24 months (Franco 2026) |
| iTIND | MIST | 25–75 mL | No obstructing median lobe | No new ejaculatory dysfunction reported in cited studies [2] |
| Optilume BPH | MIST | 20–80 mL; urethral length 32–55 mm (AUA 2026) | No obstructing median lobe (excluded in trials) | FDA pivotal trial through 12 months: 1/98 anejaculation, 2/98 retrograde ejaculation (physician labeling [16]) |
| PAE | Embolization | ≥ 50 mL (AUA 2026) | Favorable pelvic arterial anatomy | Erectile function may be similar to TURP; ejaculatory disorders may be fewer (low certainty) [10] |
| Catheter Pathway | Drainage / Bridge | — | Retention, frailty, bridging | — |
Volume ranges come from different kinds of source: the 30–80 mL TURP range is an EAU strong recommendation.[2] The June 2025 FDA clearance indicates Rezūm for men aged 50 or older with 30–150 mL prostates and central-zone and/or median-lobe hyperplasia.[15] Its earlier FDA clearance indicated 30–80 mL with the same anatomic coverage.[13] The table’s iTIND 25–75 mL entry is the FDA-reviewed MT-03 study selection range.[20] The AUA 2026 statements for PUL, water vapor, robotic waterjet, iTIND and the drug-coated BPH balloon carry their own size limits, as listed in the table. The table’s Aquablation 30–150 mL span combines the WATER 30–80 mL trial and separate WATER II 80–150 mL cohort.[2] The GreenLight FDA clearance lists no prostate-volume cutoff;[19] EAU 2026 strongly recommends 80/120/180-W PVP for 30–80 mL prostates.[2] EAU 2026 sets its own strong-recommendation ranges: 30–80 mL for TURP, laser vaporization (80 W KTP, 120 W LBO, 180 W LBO) and Aquablation, under 30 mL without a middle lobe for TUIP, under 70 mL without a middle lobe for PUL, and above 80 mL for open prostatectomy when endoscopic enucleation is unavailable.[2] HoLEP has no size limit in EAU. EAU makes weak recommendations for Tm:YAG and bipolar enucleation, bipolar vaporization and PAE, and none for water vapor therapy, iTIND or the drug-coated balloon, which it lists as under investigation.[2]
Follow-Up Anchors
| Treatment | First reassessment | What counts as response |
|---|---|---|
| Behavioral therapy | 6-12 weeks | Lower bother, fewer urgency/nocturia episodes, stable PVR |
| Alpha blocker | Days to 4 weeks | IPSS decrease >=3, better stream, fewer voiding symptoms |
| Tadalafil | 4-6 weeks | IPSS decrease >=3 plus sexual-function benefit if ED present |
| Anticholinergic / beta3 agonist | 4-8 weeks | Fewer urgency/frequency episodes without unsafe PVR rise |
| 5-ARI | 3-6 months | Symptom stability or improvement, prostate shrinkage, reduced progression risk; PSA interpretation adjusted |
| MIST | 6 weeks, 3 months, 12 months | IPSS / QoL response, catheter-free voiding, no recurrent retention |
| TURP / enucleation / simple prostatectomy | 4–6 weeks after catheter removal; further review if symptoms persist or adverse events occur[2] | Assess symptom relief, flow, PVR, erectile and ejaculatory function; monitor incontinence, stricture, and BNC |
AUA 2026 advises evaluating every man within six months of starting treatment, with a standardized symptom score and an adverse-event review; most medications show effect by about 4 weeks, while 5-ARIs take 3-6 months.[11]
Podcasts
References
1. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men: a review. JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045
2. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. 2026 update. EAU
3. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11-19. doi:10.1097/JU.0000000000003698
4. Arnold MJ, Gaillardetz A, Ohiokpehai J. Benign prostatic hyperplasia: rapid evidence review. Am Fam Physician. 2023;107(6):613-622. AAFP
5. Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248-257. doi:10.1056/NEJMcp1106637
6. Franco JVA, Jung JH, Imamura M, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database Syst Rev. 2021;7:CD013656. doi:10.1002/14651858.CD013656.pub2
7. Cornu JN, Zantek P, Burtt G, et al. Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis. Eur Urol. 2023;83(6):534-547. doi:10.1016/j.eururo.2023.02.028
8. Hwang EC, Jung JH, Borofsky M, Kim MH, Dahm P. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019;2:CD013143. doi:10.1002/14651858.CD013143.pub2
9. Jung JH, Reddy B, McCutcheon KA, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019;5:CD012832. doi:10.1002/14651858.CD012832.pub2
10. Jung JH, McCutcheon KA, Borofsky M, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2022;3:CD012867. doi:10.1002/14651858.CD012867.pub3
11. Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline (2026). Part I: Presentation and evaluation. J Urol. 2026;216(2):143-151. doi:10.1097/JU.0000000000005097.
12. Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline (2026). Part III: Procedural and surgical management. J Urol. 2026;216(2):161-170. doi:10.1097/JU.0000000000005099.
13. US Food and Drug Administration. 510(k) Summary K150786: Rezum System (Nxthera), decision August 27, 2015; indications unchanged in K160417 and K180237. Indications for use. FDA 510(k) summary.
14. Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline (2026). Part II: Medical management. J Urol. 2026;216(2):152-160. doi:10.1097/JU.0000000000005098.
15. US Food and Drug Administration. 510(k) Summary K250584: Rezūm System. Decision June 11, 2025. FDA 510(k) summary.
16. US Food and Drug Administration. Optilume BPH Catheter System: Physician Labeling (P220029C). 2023. FDA.
17. Müllhaupt G, Hechelhammer L, Graf N, et al. "Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Obstruction: 5-year Outcomes of a Randomised, Open-label, Noninferiority Trial." Eur Urol Focus. 2024;10(5):788–795. doi:10.1016/j.euf.2024.03.001
18. Ritter M, Stein J, Barber N, et al. "WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms." Eur Urol Focus. 2026;12(2):266–274. doi:10.1016/j.euf.2026.01.006
19. US Food and Drug Administration. GreenLight XPS Laser System, 510(k) K092735: Indications for Use. 2009. FDA
20. US Food and Drug Administration. iTind System, DEN190020: De Novo Decision Summary. 2020. FDA.
21. Abolazm AE, El-Hefnawy AS, Laymon M, et al. "Ejaculatory Hood Sparing versus Standard Laser Photoselective Vaporization of the Prostate: Sexual and Urodynamic Assessment through a Double Blinded, Randomized Trial." J Urol. 2020;203(4):792-801. doi:10.1097/JU.0000000000000685